AbbVie Seminar - Immuno-Oncology: Where We Are and What's Next Diane Hollenbaugh, PhD, Executive Director, Immuno-Oncology Discovery, AbbVie Targeting the immune system to target cancer has led to new therapeutics with incredible impact on patients' lives, and there is more to come. The talk will provide an overview of the state of the field in Immuno-Oncology, the many approaches being taken, some potential potholes, and opportunities for the future. Diane Hollenbaugh has extensive experience in the biopharmaceutical industry in discovery, research and early development. Diane leads the Discovery Team with a focus on Immuno-Oncology at AbbVie Redwood City.
October 9, 2018 at 12:30 PM 953 Indiana Street, San Francisco Lunch Served
November 01, 2018 3:30 - 6:00 PM 733 Industrial Rd, San Carlos
Come meet our residents, tour our new space in San Carlos, and hear about our exciting plans for the future. There will be posters from our companies, a live band, and an opportunity to chat with our partners and staff.
Dorian Therapeutics is an anti-aging company focusing on blocking the process of cellular senescence at early stages. The company develops therapeutics to modulate stem cell pathways affected during aging.
Soteria Biotherapeutics is developing next-generation T-cell therapies, with improved efficacy and safety, for the treatment of cancer.